یکشنبه 18 خرداد 1404
[Archive]
دوره 31، شماره 146 - ( 4-1402 )
جلد 31 شماره 146 صفحات 249-244 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mokhlesi O, Sadeghian M H, Shajiei A, Sheikhi M, Siyadat P, Kooshyar M M, et al . Frequency of T315I Mutation in Patients with Chronic Myeloid Leukemia Before and During Imatinib Treatment: A Study in North-East of Iran. J Adv Med Biomed Res 2023; 31 (146) :244-249
URL: http://journal.zums.ac.ir/article-1-6845-fa.html
URL: http://journal.zums.ac.ir/article-1-6845-fa.html
Frequency of T315I Mutation in Patients with Chronic Myeloid Leukemia Before and During Imatinib Treatment: A Study in North-East of Iran. Journal of Advances in Medical and Biomedical Research. 1402; 31 (146) :244-249
چکیده: (3328 مشاهده)
Background and Objective: Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by an aberrant BCR-ABL fusion protein. Imatinib mesylate (IM) is a tyrosine kinase inhibitor that induces clinical remissions in chronic-phase CML patients. The T315I mutation at the gatekeeper residues of BCR-ABL confers resistance to both IM and second-generation TKIs, including dasatinib and nilotinib. Our objective was to determine the prevalence of T315I mutation between two groups of CML patients before and during Imatinib treatment in North-East of Iran.
Materials and Methods: This study was conducted on 100 newly diagnosed cases of CML (before commencing IM treatment) and 25 IM-resistant CML patients. PCR-RFLP, ASO-PCR, and direct sequencing were performed to detect T315I mutations.
Results: The median age of newly-diagnosed and IM-resistant patients was 48±14 and 50±12.3 years, respectively. Males/Females ratio was 1 and 1.08 for newly diagnosed and IM-resistant patients, respectively. There was no significant difference regarding the age and sex between the two groups. During the study, T315I mutational analysis was performed for all 125 patients. The prevalence of T315I mutation was 0% and 4% for newly-diagnosed and IM-resistant patients, respectively. T315I mutation was not detected before IM administration, although it was detected in 1 (4%) among resistant patients who were at least 6-months on IM treatment.
Conclusion: These observations suggest that T315I mutation may be categorized as secondary resistance and induce clonal expansion due to BCR/ABL instability. Hence, BCR-ABL mutations are less likely to appear before the onset of treatment, as presented in our study.
نوع مطالعه: مقاله پژوهشی |
موضوع مقاله:
Medical Biology
دریافت: 1401/4/19 | پذیرش: 1401/10/28 | انتشار: 1402/4/5
دریافت: 1401/4/19 | پذیرش: 1401/10/28 | انتشار: 1402/4/5
فهرست منابع
1. An X, Tiwari AK, Sun Y, et al.BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010; 34(10):1255-68. [DOI:10.1016/j.leukres.2010.04.016] [PMID]
2. Zhang H, Zhu M, Li M, et al. Mechanistic insights into co-administration of allosteric and orthosteric drugs to overcome drug-resistance in T315I BCR-ABL1. Front Pharmacol. 2022; 13: 862504. [DOI:10.3389/fphar.2022.862504] [PMID] [PMCID]
3. Oaxaca DM, Yang-Reid SA, Ross JA, Rodriguez G, Staniswalis JG, Kirken RA. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Tumour Biol. 2016;37(9):12643-54. [DOI:10.1007/s13277-016-5179-7] [PMID] [PMCID]
4. Mat Yusoff Y, Abu Seman Z, Othman N, et al. Prevalence of BCR-ABL T315I mutation in Malaysian patients with imatinib-resistant chronic myeloid leukemia. Asian Pac J Cancer Prev. 2018; 19(12): 3317-20. [DOI:10.31557/APJCP.2018.19.12.3317] [PMID] [PMCID]
5. Wongboonma W, Thongnoppakhun W, Auewarakul CU. A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients. J Hematol Oncol. 2011; 4: 7. [DOI:10.1186/1756-8722-4-7] [PMID] [PMCID]
6. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303-9. [DOI:10.1182/blood-2006-09-047266] [PMID]
7. Karimiani EG, Marriage F, Merritt AJ, Burthem J, Byers RJ, Day PJ. Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein. Exp Hematol. 2014;42(3):183-191. [DOI:10.1016/j.exphem.2013.11.006] [PMID]
8. Khorashad JS, Kelley TW, Szankasi P, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013 17;121(3):489-98. [DOI:10.1182/blood-2012-05-431379] [PMID] [PMCID]
9. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 2002 15;100(8):3041-4. [DOI:10.1182/blood-2002-05-1361] [PMID]
10. Verma M, Karimiani EG, Byers RJ, Rehman S, Westerhoff HV, Day PJ. Mathematical modelling of miRNA mediated BCR.ABL protein regulation in chronic myeloid leukaemia vis-a-vis therapeutic strategies. Integr Biol (Camb). 2013;5(3):543-54. [DOI:10.1039/c3ib20230e] [PMID]
11. Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. Biochemical and biophysical research communications. 2004;319(4):1272-5. [DOI:10.1016/j.bbrc.2004.05.113] [PMID]
12. Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol. 2013;4(2):103-17. [DOI:10.1177/2040620712468289] [PMID] [PMCID]
13. Nicolini FE, Chabane K, Tigaud I, Michallet M, Magaud JP, Hayette S. BCR-ABL mutant kinetics in CML patients treated with dasatinib. Leuk Res. 2007;31(6):865-8. [DOI:10.1016/j.leukres.2006.12.003] [PMID]
14. Chahardouli B, Zaker F, Mousavi SA, et al. Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance. Hematol. 2013;18(3):158-62. [DOI:10.1179/1607845412Y.0000000050] [PMID]
15. Hayette S, Michallet M, Baille ML, Magaud JP, Nicolini FE. Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients. Leuk Res. 2005;29(9):1073-7. [DOI:10.1016/j.leukres.2005.02.006] [PMID]
16. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. . Cancer Cell. 2002;2(2):117-25. [DOI:10.1016/S1535-6108(02)00096-X] [PMID]
17. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. New Eng J Med. 2013;369(19):1783-96. [DOI:10.1056/NEJMoa1306494] [PMID] [PMCID]
18. Breccia M, Pregno P, Spallarossa P, et al. Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. Ann Hematol. 2017;96(4):549-58. [DOI:10.1007/s00277-016-2820-x] [PMID]
19. Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-35. [DOI:10.1016/S1470-2045(10)70233-3] [PMID]
20. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002 1;100(3):1014-8. [DOI:10.1182/blood.V100.3.1014] [PMID]
21. Nicolini FE, Basak GW, Soverini S, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood. 2011 17;118(20):5697-700. [DOI:10.1182/blood-2011-07-367326] [PMID] [PMCID]
22. Nicolini FE, Ibrahim AR, Soverini S, et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98(10):1510-6. [DOI:10.3324/haematol.2012.080234] [PMID] [PMCID]
23. Nicolini FE, Mauro MJ, Martinelli G, et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 2009;114(26):5271-8. [DOI:10.1182/blood-2009-04-219410] [PMID] [PMCID]
24. Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007;110(12):4005-11. [DOI:10.1182/blood-2007-03-080838] [PMID]
25. Kim SH, Kim D, Kim DW, et al. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol Oncol. 2009;27(4):190-7. [DOI:10.1002/hon.894] [PMID]
26. Elias MH, Baba AA, Azlan H, et al. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-frequency and clinical outcome. Leuk Res. 2014;38(4):454-9. [DOI:10.1016/j.leukres.2013.12.025] [PMID]
27. Goranova-Marinova V, Linev A, Ivanov HJ, Zheljazkov I, Stoyanova V, Grudeva-Popova Z. Clinical characteristics, disease evolution and survival in patients with chronic myeloid leukemia, BCR-ABL1 (+) and T315I mutation. Folia Medica. 2021;63(5):670-5. [DOI:10.3897/folmed.63.e63366] [PMID]
28. Soverini S, De Benedittis C, Papayannidis C, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120(7):1002-9. [DOI:10.1002/cncr.28522] [PMID]
29. Markose P, Chendamarai E, Balasubramanian P, et al. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. Leuk Lymphoma. 2009;50(12):2092-5. [DOI:10.3109/10428190903332486] [PMID]
30. Mauro MJ. T315I, more or less, predicts for major molecular response: the devil is in the details! Haematologica. 2013;98(5):665-6. [DOI:10.3324/haematol.2013.084251] [PMID] [PMCID]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
